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ABSTRACT 
The peroxisome proliferator-activated receptor gamma (PPARγ) agonist 
rosiglitazone has recently been withdrawn from the European market and its 
use has been restricted in the US due to its undesirable effects which were 
considered to outweigh its benefits.  Literature indicates that there are two 
agonist bound conformations of the PPARγ as exemplified by its binding to 
rosiglitazone (PDB ID; 1FM6) and to farglitazar (PDB ID; 1FM9).  This study 
aims to explore these two conformations, and to evaluate whether they 
should be targeted separately in the context of drug design studies.  
Furthermore, it was aimed to design a series of molecules with the potential 
to act as leads in a drug design process and the capability of agonist activity 
at the PPARγ with an acceptable side effect profile.  In silico ligand binding 
affinities (pKd) of rosiglitazone and farglitazar within their cognate receptors 
were 6.62 and 9.70 respectively.  The farglitazar conformer that bound 
optimally within the rosiglitazone bound PPARγ ligand binding pocket was 
identified and its binding affinity (pKd) re-determined.  An analogous 
conformational analysis of rosiglitazone within the farglitazar bound PPARγ 
ligand binding pocket was carried out.  The binding affinities (pKd) for these 
optimum conformations were 8.12 and 6.16 respectively.  De novo novel 
structures were generated in silico based on the tyrosine-agonist farglitazar 
and its cognate ligand binding pocket.  Moreover, analysis of the binding 
modality of farglitazar indicates that this molecule accesses the PPARγ ligand 
binding pocket more completely than does rosiglitazone.  Binding affinity 
studies have shown that the PPARγ ligand binding pocket adopts diverse 
ligand driven conformations. 
INTRODUCTION: The recent advance in the 
development of new remedies for the treatment of 
type 2 diabetes mellitus is a result of the increase in 
the incidence of this disease, as well as the high 
percentage of associated co-morbidities and deaths 1.  
The thiazolidinediones are peroxisome proliferator-
activated receptor gamma (PPARγ) agonists which 
were designed to manage type 2 diabetes mellitus 
owing to their ability to improve insulin sensitivity 
through actions which are completely different from 
those of other oral hypoglycaemic drugs 2.  
Unfortunately, these drugs have been associated with 
a number of undesirable effects including fluid 
retention, weight gain 3, and an increase in risk of 
myocardial infarction 4.  
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 This resulted in rosiglitazone being withdrawn from 
the European market, and in its restricted use within 
the US 5.  The different clinical profiles observed when 
different thiazolidinediones were compared are 
indicative of the potential for continued innovation 
within this class of drugs 6. 
The study investigates, through a de novo drug design 
approach, two different bound conformations of the 
PPARγ receptor, as exemplified by its binding to 
rosiglitazone and that to farglitazar. These dissimilar 
conformations are the result of amino acid side chains 
orienting themselves differently around different 
ligands within the same receptor 7.  This is particularly 
encouraging from a drug design perspective since the 
PPARγ ligand binding pocket (LBP) appears to be 
capable of accommodating structurally diverse 
molecules.   
This signifies that it would be possible to identify novel 
structures with the ability to bind to, and potentially 
activate this receptor and achieve normo-glycaemic 
status among type 2 diabetics for an acceptable side-
effect profile. Salam et al. (2008) 8 sought to exploit 
the crystallographic data describing the varied 
conformations of the PPARγ LBP by performing a 
virtual screening exercise using a previously 
constructed in-house natural product library in order 
to indentify novel molecules with known affinity for 
the PPARγ and promising in vivo bioavailability.  The 
current study emulates that of Salam et al., (2008) 8, 
but differs essentially in the adoption of a de novo 
based approach using the structure of the previously 
identified PPARγ agonist farglitazar.   
Tyrosine-based PPARγ agonists, such as farglitazar, 
have shown potent glucose-lowering activity in vivo9 
and have therefore been chosen as the basis for 
development of novel high affinity molecules in this 
study.   
Method: The two agonist- bound conformations for 
the PPARγ receptor described by Salam et al., (2008) 8, 
highlighting the existence of the different PPARγ LBP 
conformations, obtained from the Protein Data Bank 
(PDB) 10 were used as templates in this study. These 
were PDB ID 1FM6 7, describing the holo- co-ordinates 
of the PPARγ bound to rosiglitazone, and PDB ID 1FM9 
7, describing the holo- co-ordinates of the PPARγ 
bound to farglitazar. PPARγ is naturally found dimerised 
with the retinoid X heterodimeric receptor (RXR) which 
endogenously binds retinoic acid 11.  The 
crystallographic deposition 1FM6 consists of two 
PPARγ/RXR dimers which are bound together to form a 
tetramer, whereas the crystallographic deposition 
1FM9 appears as a single PPARγ/RXR dimer7 (Figure 1). 
 
A 
 
B 
FIGURE 1: 1FM6 (A) AND 1FM9 (B) AS FOUND IN THE PDB; THE 
RXR RECEPTORS CAN BE SEEN BOUND TO RETINOIC ACID 
(YELLOW), AND THE PPARΓ RECEPTORS BOUND TO 
ROSIGLITAZONE (RED). Generated using Molsoft ICM Browser® 
12
. 
The crystallographic depositions were read into 
Sybyl®13 and simplified in silico in preparation for 
estimation of ligand binding affinity (LBA) (pKd).  
Simplification was performed in such a way that the 
bound coordinates of the ligand were retained and 
used as templates for further drug modeling.  The 
simplification process included the;  
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1. Removal of water molecules owing to the fact that 
they were considered superfluous to ligand 
binding. 
2. Removal of one dimer (in the case of 1FM6 which is 
found as a tetramer) and associated ligand. 
3. Removal of the co-factors since it has been 
established that they do not alter ligand binding to 
the PPARγ. 
4. Extraction of the bound small molecules 
rosiglitazone and farglitazar respectively in 
preparation for LBA (pKd) estimation.   
The retinoic acid bound to the retained RXR moiety 
was not removed owing to the fact that literature 
indicates that retinoic acid causes a conformational 
change in the PPARγ moiety which alters LBA of the 
latter receptor for its cognate ligand 7.   
The final outcome was a holo RXR receptor bound to 
the apo form of PPARγ for both crystallographic 
depositions. The bound co-ordinates of the small 
molecules rosiglitazone and farglitazar were saved 
separately.  Estimation of binding affinities was carried 
out using the score algorithm 14. 
High affinity conformers of farglitazar and rosiglitazone 
were then generated using the Similarity Suite in 
Sybyl® 13, which has the ability to generate viable 
binding conformations of potential ligands for an 
active site based on common 3D volume and proximity 
of important binding moieties. Farglitazar was 
therefore optimally docked into the rosiglitazone 
bound PPARγ LBP (1FM6) 7 and rosiglitazone into the 
farglitazar bound PPARγ LBP (1FM9) 7.  The result of 
this process was a preset number (n=21) of the highest 
affinity conformers for each ligand, output in a single 
mol2 file, the contents of which were then individually 
visualized with ligand binding affinity (pKd) and energy 
being calculated in XScore® 14. 
Rosiglitazone (the molecule co-crystallized with 1FM6) 
and the highest binding affinity (pKd) conformer of 
farglitazar were both used as probes in order to 
generate 3D maps and pharmacophores of the 
rosiglitazone bound PPARγ LBP (1FM6).  These were 
then compared in order to determine and evaluate the 
extent of any differences between the two.  LBP 
mapping and general pharmacophore identification 
was carried out in LigBuilder® 16, a program that 
designs small molecules de novo within the constraints 
of a pre-defined binding pocket. The first module of 
LigBuilder® 16, namely Pocket, was used in this part of 
the study. 
The next part of the study was carried out in order to 
design novel molecules with antidiabetic properties 
and a more acceptable side-effect profile, which do not 
fall under the glitazone class. Molecular modeling was 
carried out using Sybyl® 13 and de novo design was 
executed using LigBuilder 16.  The seed was essentially 
the tyrosine moiety in farglitazar which was planted 
into the farglitazar bound PPARγ LBP at a locus 
analogous to that which it would have occupied had 
the farglitazar molecule itself been docked 17 (Figure 
2).   
 
FIGURE 2:  STRUCTURE OF FARGLITAZAR WITH ITS TYROSINE 
BACKBONE HIGHLIGHTED.  Drawn using Accelrys Draw 4.0 ® 
15
.   
Growing sites were then established through atom 
type assignation in which the atom type H.spc was 
recognizable to the Grow algorithm in LigBuilder®16 as 
a site on which fragment attachment could occur.  Two 
seeds were used for this study.  
Both seeds had two potential growing sites, the first, 
that on the hydroxyl hydrogen attached to the 
benzene ring which was common to both.  The 
difference lay in which of the two amine hydrogens 
was allowed growth as depicted in Figure 3 below.  
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FIGURE 3:  TYROSINE BACKBONE OF FARGLITAZAR CREATED AS 
SEED; SEED A (TOP), SEED B (BOTTOM). Drawn using Accelrys 
Draw 4.0® 
15
. 
The result of this process was a number of analog 
families which were ranked according to predicted 
binding affinity (pKd) and bioavailability.  The highest 
rankers in each family were chosen based on Lipinski’s 
Rule of 5 18 and were narrowed down on the basis of 
compliance with the Rule of 3 19, 20 .  The 82 highest 
rankers were then further reduced based on binding 
affinity (pKd). 
RESULTS: The binding affinity (pKd) of rosiglitazone 
with its cognate receptor (1FM6) was 6.62 and that of 
farglitazar with its cognate receptor (1FM9) was 9.70.  
Twenty-one viable binding conformations of each 
ligand within its alternate receptor conformation were 
generated. The best binding conformer of farglitazar 
for the rosiglitazone bound LBP (1FM6) had a binding 
affinity (pKd) of 8.12 and the best binding conformer of 
rosiglitazone for the farglitazar bound LBP (1FM9) was 
6.16 (Table 1).   
TABLE 1: BEST BINDING CONFORMERS OF FARGLITAZAR AND ROSIGLITAZONE FOR THE ALTERNATE RECEPTORS. STRUCTURAL IMAGES 
GENERATED USING MOLSOFT ICM BROWSER® 
12
. 
 
Best binding conformer of farglitazar within PPARγ 
LBP 1FM6 
Best binding conformer of rosiglitazone within PPARγ 
LBP 1FM9 
Structure 
  
LBA (pKd) 8.12 6.16 
 
Figure 4 shows the LBA (pKd) and binding energy 
(kcalmol-1) for the 21 highest affinity conformers of 
rosiglitazone that were generated within the farglitazar 
bound PPARγ.  The conformation with the greatest LBA 
(pKd=6.16) is shown in red. 
Similarly, the LBA (pKd) and binding energy (kcalmol-1) 
for the 21 highest affinity conformers of farglitazar that 
were generated within the rosiglitazone bound PPARγ 
can be seen in Figure 5 below.  The conformation with 
the greatest LBA (pKd=8.12) is shown in red. 
Table 2 shows the in silico LBAs (pKd) of rosiglitazone 
and farglitazar bound to their cognate receptors 
compared with the LBAs (pKd) of their optimum 
conformers bound to the alternative receptor 
conformation. 
The visual outputs of the mapped LBP’s can be seen in 
Figures 6 and 7. 
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FIGURE 4: GRAPH OF BINDING AFFINITY (pkd)/BINDING ENERGY 
(kcalmol
-1
) FOR THE 21 CONFORMATIONS OF FARGLITAZAR FOR 
THE ALTERNATE PPARγ LBP (1FM6) 
 
FIGURE 5: GRAPH OF BINDING AFFINITY (pKd)/Binding Energy 
(kcalmol
-1
) FOR THE 21 CONFORMATIONS OF ROSIGLITAZONE 
FOR THE ALTERNATE PPARγ LBP (1FM9) 
TABLE 2: THE IN SILICO LBA (pKd) OF ROSIGLITAZONE AND FARGLITAZAR FOR THEIR COGNATE PPARγ RECEPTORS COMPARED WITH 
THE IN SILICO LBA (pKd) OF THE HIGHEST AFFINITY CONFORMERS FOR THE ALTERNATIVE PPARγ RECEPTORS 
Rosiglitazone (Cognate Receptor 1FM6) Farglitazar (Cognate Receptor 1FM9) 
LBA for its cognate receptor; 1FM6 (pKd) 6.62 LBA for its cognate receptor; 1FM9 (pKd) 9.70 
LBA of conformer 021 for the alternative receptor; 1FM9 
(pKd) 
6.16 
LBA of conformer 019 for the alternative receptor; 1FM6 
(pKd) 
8.12 
 
  
FIGURE 6: THE LBP OF THE ROSIGLITAZONE BOUND PPARγ AS DESCRIBED IN PDB ID: 1FM6 (LEFT) AND ITS RESPECTIVE 
PHARMACOPHORE (RIGHT).  HYDROGEN BOND DONOR GRIDS ARE COLOURED IN BLUE, HYDROGEN BOND ACCEPTOR GRIDS IN RED 
AND HYDROPHOBIC GRIDS IN WHITE. Images generated using Molsoft ICM Browser® 
12
. 
                          Ciantar et al., IJPSR, 2012; Vol. 3(8): 2550-2561                                   ISSN: 0975-8232 
                                           Available online on www.ijpsr.com                                        2555 
  
FIGURE 7: THE LBP OF THE FARGLITAZAR BOUND PPARΓ AS DESCRIBED IN PDB ID: 1FM6 (LEFT), AND ITS RESPECTIVE 
PHARMACOPHORE (RIGHT).  FARGLITAZAR HERE IS NOT NATIVE (ROSIGLITAZONE) TO THE DESCRIBED CONFORMATION OF THE PPARγ 
LBP.  HYDROGEN BOND DONOR GRIDS ARE COLORED IN BLUE, HYDROGEN BOND ACCEPTOR GRIDS IN RED AND HYDROPHOBIC GRIDS 
IN WHITE.  Images generated using Molsoft ICM Browser® 
12
. 
Multiple families of compounds were generated for 
each of the seeds all containing potential lead 
compounds for the PPARγ receptor.  Twenty-seven 
highest rankers for seed A and 55 for seed B were 
identified and selected.  None of the generated 
molecules fell within the Rule of 3 criteria 19.  The Rule 
of 3 19 is a more stringent application of Lipinski’s Rule 
of 5 18 which is typically adhered to during lead 
molecule selection owing to the fact that it provides 
the leeway for structural alterations that are carried 
out during iterative optimization rounds that would 
consequently result in Rule of 5 18 compliant end 
product molecules.  Out of the selected molecules, 18 
ligands were chosen as potential ligands for a novel 
drug design study – 2 resulting from seed A, and 16 
from seed B (Tables 3 and 4). 
TABLE 3: HIGHEST RANKERS OF EACH FAMILY FOR SEED A.  Structural images and IUPAC names were generated using; Molsoft ICM 
Browser®
12
, Accelrys Draw 4.0® 
15
, and Virtual Computational Chemistry Laboratory® 
21
. 
IUPAC Name Binding Affinity (pKd)  
(3Z,5E)-6-[2-[4-[(2S)-2-[[(4Z)-5-ethylhepta-4,6-
dienyl]amino]-3,3-dihydroxy-propyl]phenyl]ethyl]-4-
[(E)-3-hydroxyprop-1-enyl]octa-3,5,7-trienal 
9.92 
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(2E,4E,6E,8R)-4-allyl-6-ethyl-8-[4-[(2S)-2-[[(3R)-3-
ethylhexyl]amino]-3,3-dihydroxy-propyl]phenyl]octa-
2,4,6-triene-1,1,8-triol 
9.95 
 
TABLE 4: HIGHEST RANKERS OF EACH FAMILY FOR SEED B.  Structural images and IUPAC names were generated using; Molsoft ICM 
Browser®
12
, Accelrys Draw 4.0®
15
, and Virtual Computational Chemistry Laboratory® 
21
. 
IUPAC Name Binding Affinity (pKd) Structure 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3E,5E)-
6-[(1R,3S)-3-ethylcyclopentyl]deca-3,5-dienyl]indane-
2-carboxamide 
9.15 
 
(2R)-N-[(3E)-3-[(5R)-5-[(3aS,7aS)-2,3,3a,6,7,7a-
hexahydro-1H-inden-5-yl]cyclohex-2-en-1-
ylidene]propyl]-5-[(2S)-2-amino-3,3-dihydroxy-
propyl]indane-2-carboxamide; (2R)-5-[(2S)-2-amino-
3,3-dihydroxy-propyl]-N-[(3E,5E)-6-[(1R,3S)-3-
ethylcyclopentyl]deca-3,5-dienyl]indane-2-
carboxamide 
8.16 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3E)-4-
(1-methyl-2H-quinolin-6-yl)octa-3,7-dienyl]indane-2-
carboxamide 
7.57 
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(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(E)-4-
[(3S,4S)-4-ethyl-3-methyl-cyclohexen-1-yl]but-3-
enyl]indane-2-carboxamide 
7.99 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3Z,5E)-
4-[(Z)-1-cyclopentylprop-1-enyl]-6-methyl-octa-3,5-
dienyl]indane-2-carboxamide 
7.91 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3Z,5E)-
4-[(Z)-1-cyclopentylprop-1-enyl]-6-methyl-octa-3,5-
dienyl]indane-2-carboxamide; (2R)-5-[(2S)-2-amino-
3,3-dihydroxy-propyl]-N-[(3E,5E)-6-[(1S,2S)-2-
isopropenylcyclopent-3-en-1-yl]nona-3,5-
dienyl]indane-2-carboxamide 
8.07 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3E,5E)-
6-[(1S,2S)-2-isopropenylcyclopent-3-en-1-yl]nona-3,5-
dienyl]indane-2-carboxamide 
8.07 
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(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3E,5E)-
6-[(1S,2S)-2-isopropenylcyclopent-3-en-1-yl]nona-3,5-
dienyl]indane-2-carboxamide; (2R)-5-[(2S)-2-amino-
3,3-dihydroxy-propyl]-N-[(3E)-3-[(1R)-1-vinyl-2,4-
dihydro-1H-phenanthren-3-ylidene]propyl]indane-2-
carboxamide 
7.53 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(3E)-3-
[(2R,3S,5R)-2-[(1Z)-hepta-1,6-dienyl]-3,5-dimethyl-
cyclohexylidene]propyl]indane-2-carboxamide 
7.98 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(E)-4-(1-
vinyl-2-naphthyl)but-3-enyl]indane-2-carboxamide 
 
8.31 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(Z,9S)-9-
[(1S)-cyclopent-2-en-1-yl]dec-2-enyl]indane-2-
carboxamide 
 
8.86 
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(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(E)-4-
[(4R,6S)-4-[(1S)-cyclohex-2-en-1-yl]-4,6-dimethyl-
cyclohexen-1-yl]but-3-enyl]indane-2-carboxamide; 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(Z,9S)-9-
[(1S)-cyclopent-2-en-1-yl]dec-2-enyl]indane-2-
carboxamide 
8.66 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(Z)-7-
[(1S,5S)-5-ethylcyclopent-2-en-1-yl]hept-2-
enyl]indane-2-carboxamide 
 
8.02 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(1S)-4-
[(1R,5S)-5-[(1R)-cyclopent-2-en-1-yl]-2-ethyl-cyclohex-
2-en-1-yl]-1-methyl-butyl]indane-2-carboxamide; (2R)-
5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[(Z)-7-
[(1S,5S)-5-ethylcyclopent-2-en-1-yl]hept-2-
enyl]indane-2-carboxamide 
7.89 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[2-
[(1S,4R,5S)-5-cyclohexyl-4-methyl-cyclopent-2-en-1-
yl]ethyl]indane-2-carboxamide 
7.44 
 
(2R)-5-[(2S)-2-amino-3,3-dihydroxy-propyl]-N-[2-
[(1S,4R,5S)-5-cyclohexyl-4-methyl-cyclopent-2-en-1-
yl]ethyl]indane-2-carboxamide; (2R)-5-[(2S)-2-amino-
3,3-dihydroxy-propyl]-N-[(2Z,5E,7E)-5-[(Z)-3-(m-
tolyl)prop-1-enyl]nona-2,5,7-trienyl]indane-2-
carboxamide 
7.43 
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DISCUSSION: This study specifically aimed to 
demonstrate that the LBP of PPARγ adopted distinct 
conformations which were ligand driven – specifically 
one distinct conformation being adopted when PPARγ 
was bound to rosiglitazone (PDB ID; 1FM6) and 
another being adopted when PPARγ was bound to 
farglitazar (PDB ID; 1FM9).  In addition, it sought to 
propose viable alternatives to the currently available 
thiazolidinediones, owing to the fact that their flagship 
molecule rosiglitazone while being recognised for its 
superior hypoglycaemic and dyslipidaemic effects has 
had its use completely withdrawn or restricted 5 due to 
its unacceptable side effect profile 3, 4. 
Binding affinities decreased when rosiglitazone and 
farglitazar were bound to the alternate receptor 
conformations, in comparison with the binding 
affinities measured for these two ligands with their 
cognate receptor conformations. An interesting 
observation is that the lower affinity of rosiglitazone 
and the higher affinity of farglitazar appear to be 
preserved in the cognate and alternative 
conformations of the PPARγ LBP in each case.   
Rosiglitazone with preserved bound co-ordinates, has a 
predicted in silico affinity of pKd 6.62 for its cognate 
receptor. This changed to pKd 6.16 when the highest 
affinity conformer for the farglitazar bound 
conformation of the PPARγ receptor was calculated. 
Similarly, farglitazar, with preserved bound co-
ordinates was calculated to have a predicted in silico 
affinity (pKd) of 9.7 which decreased to 8.12 when the 
LBA (pKd) of the highest affinity conformer for the 
rosiglitazone bound conformation of the PPARγ 
receptor was calculated. The implications of this part 
of the study consequently are that; 
 The receptors are in fact different and may be 
used as separate targets in a drug design 
project.   
 The structural conformations of the highest 
affinity ligands of rosiglitazone and farglitazar 
for their alternative receptor conformations 
were identified, and could be put forward as 
templates for rigidification in bioisosteric 
exercises. 
Mapping of the PPARγ LBP and generating proposed 
pharmacophoric structures using rosiglitazone bound 
to its cognate receptor conformation (1FM6) and the 
best affinity conformer of farglitazar bound with the 
rosiglitazone bound LBP (1FM6) was carried out in 
order to further support the notion that the PPARγ 
adopts distinct conformations which are ligand driven 
and dependant.   
In fact, two different LBP maps were obtained and 
similarly, the predicted pharmacophores are not 
identical.  Given that the receptor conformation being 
assessed is the same (1FM6) and that the variable is 
only the ligand, we conclude that the ligands are 
accessing the LBP at different levels.   
This is understandable when we take into account the 
fact that 2°, 3° and 4° structures of a protein are a 
consequence of the hydrophobic effect which is the 
tendency of a protein to expose its hydrophilic 
residues to the external environment, and to hide its 
hydrophobic residues in its core.   
However, protein structure remains a function of 1° 
protein structure, and as a result some hydrophilic 
amino acids may be present in the hydrophobic core 
and vice versa.  It is these unstable amino acids that 
detract from the stability and increase the potential 
energy of the protein and create the LBP which makes 
ligand binding the final step of protein folding.   
This explains how and why a protein will adopt 
different conformations around different ligands, as 
they access different unstable amino acids and create a 
ligand protein complex that has different energy and 
stability. 
A new series of non-thiazolidinedione drugs have been 
identified in silico.  These novel molecules have a 
number of advantages which include high binding 
affinities (in silico), alternative binding modalities, and 
Lipinski’s Rule of 5 18 compliance. 
In conclusion, this study may be considered a point of 
departure for further design of drug like molecules of 
demonstrable affinity for the PPARγ.   
 
 
                          Ciantar et al., IJPSR, 2012; Vol. 3(8): 2550-2561                                   ISSN: 0975-8232 
                                           Available online on www.ijpsr.com                                        2561 
REFERENCES: 
1. World Health Organization (2011) Diabetes. WHO Fact sheet 
312. World Health Organization, Geneva, Switzerland. 
http://www.who.int/mediacentre/factsheets/fs312/en/. 
2. Greenfield JR, Chisholm DJ. Thiazolidinediones – Mechanism of 
Action.  Aust Prescr. 2004; 27: 67-70. 
3. Werner A. L., Travaglini M.T. A review of rosiglitazone in type 2 
diabetes mellitus. Pharmacotherapy. 2001, 21(9), 1082-1099. 
4. Home P. D., Pocock S. J., Nielsen H. B. , Gomis R. , Hanefeld M., 
Jones N. P., Komajda M., McMurray J.J.V. Rosiglitazone 
Evaluated for Cardiovascular Outcomes — An Interim Analysis. 
New Engl J Med. 2007, 357, 28-38. 
5. GSK. GSK regulatory update on Avandia following EMA and FDA 
reviews. 
http://www.gsk.com/media/pressreleases/2010/2010_pressrel
ease_10103.htm (Accessed Jan 23, 2012). 
6. Katzung B. G. Basic and Clinical Pharmacology; The McGraw-Hill 
Companies: USA, 2004. 
7. Gampe RT, Montana VG, Lambert MH, Miller AB, Bledsoe RK, 
Milburn MV et al. Asymmetry in the PPARγ/RXRα Crystal 
Structure Reveals the Molecular Basis of Heterodimerization 
among Nuclear Receptors.  Mol Cell.  2000; 5:  p.545-555. 
8. Salam NK, Huang THW, Kota BP, Kim SM, Li Y, Hibbs D. Novel 
PPAR-gamma Agonists Identified from a Natural Product 
Library: A Virtual Screening, Induced FitDocking and Biological 
Assay Study. Chem Biol Drug Des. 2008; 71: 57-70. 
9. Brown KK, Henke BR, Blanchard SG, Cobb JE, Mook R, Kaldor I, 
et al.  A Novel N-Aryl Tyrosine Activator of Peroxisome 
Proliferator-Activated Receptor-γ Reverses the Diabetic 
Phenotype of the Zucker Diabetic Fatty Rat.  Diabetes. 1999; 48: 
1415-1422. 
 
 
 
 
10. Prilusky, J. (1996), "OCA, a browser-database for protein 
structure/function." URL http://oca. weizmann.ac.il and mirrors 
worldwide. 
11. Choudhury MAI. PPARα in peroxisome proliferation: molecular 
characterisation and species differences. MSc thesis. University 
of Nottingham; 2000. 
12. Molsoft LLC. Molsoft ICM Browser; ICM group: USA, 2010. 
13. Tripos. Sybyl; Tripos International: St Louis; USA, 2010. 
14. Wang R, Liu L, Lai L, Tang Y. SCORE: a new empirical method for 
estimating the binding affinity of a protein-ligand complex. J 
Mol Model. 1998; 4: 379-394. 
15. Accelrys  Draw 4.0®. Version 4.0. Symyx Solutions, Inc. San 
Diego, CA, USA. URL. http://www .accelrys.com. 
16. Wang R, Gao Y, Lai L. Ligbuilder: a multi-purpose program for 
structure-based drug design. J Mol Model. 2000; 6: 498-516. 
17. Agostini M, Gurnell M, Savage DB, Wood WM, Smith AG, 
Rajanayagam O et al. Tyrosine Agonists Reverse with Dominant-
Negative Mutations in Human Peroxisome Proliferator-
Activated Receptor γ. Endocrin. 2004; 145(4): 1527-1538. 
18. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ.  Experimental 
and Computational Approaches to Estimate Solubility and 
Permeability in Drug Discovery and Development Settings.  Adv 
Drug Deliver Rev. 1997; 23: 3-25. 
19. Rees DC, Congreve M, Murray CW, Carr R. Fragment Based 
Lead Discovery. Nat Rev. 2004; 3: 660-672. 
20. Congreve M, Carr R, Murray C, Jhoti H. A ‘Rule of Three’ for 
Fragment-Based Lead Discovery? Drug Discov Today. 2003; 
8(19): 876-877. 
21. VCCLAB, Virtual Computational Chemistry Laboratory, http:// 
www.vcclab.org, 2005. 
 
 
Ciantar J, Shoemake C, Mangani C, Azzopardi LM and Inglott AS: 
Optimisation of Tyrosine-based Lead Molecules capable of 
modulation of the Peroxisome Proliferator-activated Receptor 
Gamma. Int J Pharm Sci Res 2012; Vol. 3(8): 2550-2561. 
